Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending

With 9.0 million cases and 1.5 million deaths estimated in 2013, tuberculosis (TB) remains one of the world's deadliest communicable diseases; however, it is slowly declining each year and it is estimated that 37 million lives were saved between 2000 and 2013 through effective diagnosis and treatment [1]. Globally, 3.5% of new and 20.5% of previously treated TB cases (480 000 people) were estimated to have been multidrug-resistant (MDR)-TB in 2013, with 9.0% of them being affected by extensively drug-resistant (XDR)-TB. Although bedaquiline is already used to treat MDR-TB neither DST nor MIC protocols are yet available to guide its use